StockNews.AI
TLX
StockNews.AI
61 days

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

1. Telix presents five abstracts at SNMMI 2025 Annual Meeting. 2. Highlights include TLX591 for advanced prostate cancer and TLX252 for CAIX1 tumors. 3. Two symposia focus on precision imaging in renal and prostate cancer. 4. The presentations underline Telix's commitment to innovation in oncology. 5. Illuccix has been approved globally; TLX591 and TLX252 seek regulatory approvals.

12m saved
Insight
Article

FAQ

Why Bullish?

Positive data presentations and pipeline strength can enhance investor confidence in TLX.

How important is it?

The news signifies clinical advancements that may drive future stock performance as products progress.

Why Long Term?

Ongoing clinical trials can lead to potential future product approvals and revenue growth.

Related Companies

ILMNNVSJNJ
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24. Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix’s TLX252 alpha therapy candidate in CAIX1 -expressing tumors in combination with DDRIs2, and clinical study data on Illuccix® impact on decision-making. Two sponsored symposia will highlight innovation in precision diagnostics, the first on CAIX-PET3 imaging in renal cancer, and the second on Illuccix PSMA-PET4 imaging in prostate cancer, including Telix’s new PSMA biopsy trial. Dr. David N. Cade, Group Chief Medical Officer, Telix, said, “Telix’s broad representation at this year’s SNMMI Annual Meeting highlights the strength of our innovative pipeline and commercial programs. Our sponsored symposia, featuring leading key opinion leaders, further reflect our commitment to expanding clinical utility and advancing cancer care so that more patients may benefit from precision theranostics.” Visit booth #408 to discuss Telix’s extensive theranostic portfolio in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), hematologic oncology, its investigational pan-cancer programs, medical technologies, and opportunities for collaboration. Presentation details are listed below (all times CDT):  Title: Impact of 68Ga-PSMA-11 PET/CT on clinical management of prostate cancer patients in different clinical settingsPresenter: Alirez Ghodsi, University of Washington, Seattle, WA Date and Time: Sunday, June 22 | 5:00 PM – 5:30 PMLocation: Hall B-CFormat: OralSession: POP03 Oncology: Clinical Diagnosis & Therapy POPsDate and Time: Sunday, June 22 | 5:30 PM – 6:15 PMLocation: Hall B-C | Science PavilionFormat: PosterSession: MTA03 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, Part 1 Title: A multinational, multicenter, prospective, randomized, controlled, open-label, Phase 3 study of 177Lu-rosopatamab tetraxetan (TLX591) in combination with standard of care versus standard of care alone in patients with PSMA-expressing prostate cancer (ProstACT Global)Presenter: Oliver Sartor, LCMC Hospitals, New Orleans, LADate and Time: Monday, June 23 | 12:30 PM – 1:15 PMLocation: Hall B-C | Science Pavilion Format: PosterSession: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, Part 2ClinicalTrials.gov ID: NCT06520345 Title: Enhanced antitumor efficacy of DNA damage response inhibitors combined with 225Ac-DOTA-girentuximab (TLX252)Presenter: Andrew Scott AM, Austin Health, Melbourne, AustraliaDate and Time: Tuesday, June 24 | 10:10 AM – 10:20 AMLocation: 223 (Convention Center)Format: OralSession: SS29 Radiopharmaceutical Developments – Preclinical and Early Phase Title: A prospective intra-individual comparison of 68Ga-PSMA-11 PET/CT and 99mTc-PSMA-GCK01/RHN001DX SPECT/CT to identify a suitable imaging surrogate for phenotyping prior to PSMA-RLTPresenter: Honest Ndlovu, Nuclear Medicine Research infrastructure (NuMeRI), Pretoria, South AfricaDate and Time: Tuesday, June 24 | 10:20 AM – 10:30 AMLocation: 223 (Convention Center)Format: OralSession: SS29 Radiopharmaceutical Developments – Preclinical and Early Phase Satellite Symposia: Title: Illuminating renal cancer: CAIX-PET imaging and the shift toward precision diagnosticsSpeakers: Shadi Esfahani, MD, Assistant Professor of Radiology, Massachusetts General Hospital, MATimothy McClure, MD, Assistant Professor of Urology and Radiology, Weill Cornell Medicine, NY Date and Time: Monday, June 23 | 6:45 – 7:45 AMLocation: R02-R03, Level 2 (Convention Center) Title: Enhancing cancer care with precision radiopharmaceuticals: Innovation in prostate cancerModerator: Munir Ghesani, MD Chief Medical Officer, United TheranosticsSpeakers: Bital Savir-Baruch, MD, Chief of Nuclear Medicine and Theranostics, Professor of Medical Imaging, University of Arizona, AZMary Jessel, Senior Vice President, Global Medical Affairs, Telix PharmaceuticalsScott Tagawa, MD, Professor of Medicine & Urology, Weill Cornell Medicine, NY Date and Time: Monday, June 23 | 5:30 - 6:30 PMLocation: R04-R05, Level 2 (Convention Center) About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple countries globally. TLX591, TLX252 and RHN001Dx have not received a marketing authorization in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: annie.kasparian@telixpharma.com Telix Media Relations (U.S.) Eliza Schleifstein ES Media Relations Email: eliza@schleifsteinpr.com    Phone: 917-763-8106 Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. 1 Carbonic anhydrase IX.2 DNA damage response inhibitors.3 Imaging of carbonic anhydrase IX with positron emission tomography.4 Imaging of prostate-specific membrane antigen with positron emission tomography.

Related News